BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dr. Magnus Persson Joins Cerecor Inc.'s Board of Directors


8/27/2012 10:35:50 AM

BALTIMORE, MD--(Marketwire - August 28, 2012) -

Cerecor Inc. announced today that Magnus Persson, MD Ph.D., has joined the company's Board of Directors. Dr. Persson was one of the original team members at Healthcap, one of the largest biotechnology venture capital firms in Europe. He became Partner before the first fund was raised in 1996, participated in raising in excess of US$ 1B in international institutional investments and was responsible for deal sourcing, screening and the monitoring of investments as Board representative. He invested in 85 Companies of which 24 have made successful IPOs in various European exchanges and on NASDAQ. Dr. Persson trained at the Karolinska Institute in Stockholm and prior to Healthcap led Phase II and III clinical programs in the Pharmaceutical Industry.

Magnus currently serves on the Board of Directors of AscendxSpine (private), ConcitPhama (private), Själbådan (private) and the Swedish Center for Medical Nanotechnology at Karolinska Institute. He has previously served on the Boards of Chemocentryx (public), Arpida (public), Tripep (public), PTC Therapeutics (private), Alba Therapeutics (private), Trigen (private), Apoxis (private), SpineVision (private), Carmot Therapeutics (private), MIPS Technology (private), Lica Pharmaceutials (private), IDEA (private), Neoventa (private) and Prolifix (public).

"Magnus has a vast network within international biopharmaceutical financing communities and has a track record of delivering value for shareholders and stakeholders while expanding the potential of those people who report to him," said Blake Paterson, MD, the CEO of Cerecor. Dr. Persson added, "I am delighted to join the Board of Directors of Cerecor and to assist its outstanding management in building a novel and truly differentiated neuroscience Company."

In addition to Drs. Persson and Paterson, Cerecor's Board is Chaired by Dr. Sol Barer and further comprised of members Dr. Gene Bauer and Mssrs. Isaac Blech, John Catsimatidis, and Cary Sucoff.

About Cerecor: Cerecor Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and organized in April 2011 in partnership with various laboratories at Johns Hopkins Medical Institute. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.


For More Information, contact:
John Dierkes
Kennedy Advisors
Email Contact
(410) 935-9334



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES